{"id":193175,"date":"2023-03-10T10:52:40","date_gmt":"2023-03-10T08:52:40","guid":{"rendered":"https:\/\/fendaf.ee\/uncategorized-et\/kui-ohutud-on-allergiaravimid\/"},"modified":"2026-11-17T18:14:59","modified_gmt":"2026-11-17T16:14:59","slug":"kui-ohutud-on-allergiaravimid","status":"publish","type":"post","link":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/","title":{"rendered":"How safe are allergy medications for dogs? How different treatments work, their risks and alternatives"},"content":{"rendered":"<p>Allergy medications for dogs can quickly relieve severe itching and noticeably improve a dog&#8217;s quality of life. But when treatment may continue long term, as an owner I want to know more than that a medicine is \u201cgenerally well tolerated\u201d. What side effects are possible? How long have they been studied? What risks should I watch for, and what do we still not know?<\/p>\n<p>Apoquel, Cytopoint, Atopica, corticosteroids, antihistamines and the newer medicines Zenrelia and Numelvi do not work in the same way. For some, side effects are understood through decades of use; for others, we have only relatively short studies. This article aims to make those differences clearer without forcing a choice between two oversimplifications: \u201cmedicines are always bad\u201d and \u201cmarketing authorisation means there is no risk\u201d.<\/p>\n<p>Allergies themselves deserve attention, too. Constant itching, scratched and damaged skin, ear infections and disrupted sleep are not minor problems. At the same time, relieving symptoms does not necessarily remove an allergen or resolve an underlying issue. That is why it is worth investigating environmental and food allergens, parasites, secondary infections and the condition of the skin barrier. We have covered <a href=\"https:\/\/fendaf.ee\/en\/health\/allergy-triggers-in-dogs\/\">allergy triggers and how to avoid them<\/a> in a separate article.<\/p>\n<p><!--more--><\/p>\n<h2>Allergy medications for dogs: a quick comparison<\/h2>\n<p>The table below gives a quick overview of how these medicines are used, their possible side effects, key official warnings and the available long-term safety data. It is neither a safety ranking nor a list ordered by frequency of use, and it does not include every possible adverse reaction. A more detailed discussion of each medicine follows the table.<\/p>\n<div class=\"fendaf-allergy-table\" style=\"width:100%;overflow-x:auto;margin:1.2em 0\">\n<table style=\"min-width:850px;width:100%;border-collapse:collapse\">\n<thead>\n<tr>\n<th scope=\"col\" style=\"background:#f0f5ec;padding:10px;border:1px solid #d8e3d3;text-align:left\">Medication<\/th>\n<th scope=\"col\" style=\"background:#f0f5ec;padding:10px;border:1px solid #d8e3d3;text-align:left\">Use<\/th>\n<th scope=\"col\" style=\"background:#f0f5ec;padding:10px;border:1px solid #d8e3d3;text-align:left\">Possible side effects<\/th>\n<th scope=\"col\" style=\"background:#f0f5ec;padding:10px;border:1px solid #d8e3d3;text-align:left\">Key official warning<\/th>\n<th scope=\"col\" style=\"background:#f0f5ec;padding:10px;border:1px solid #d8e3d3;text-align:left\">Long-term safety<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Apoquel (oclacitinib)<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Tablets. Up to 14 days twice daily, then once daily.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Digestive upset, lethargy; skin and ear infections seen during treatment.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Monitor infections and neoplastic disease; not used below 12 months.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Longer-term data exist, but health and blood results need monitoring.<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Cytopoint (lokivetmab)<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Subcutaneous injection, often every four weeks.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Rare hypersensitivity, vomiting, diarrhoea, neurological signs; very rare immune-mediated signs.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Rare serious reactions are possible; reducing itch does not treat a concurrent infection.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Longer experience and generally favourable safety data, but not risk-free.<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Corticosteroids, e.g. prednisolone<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Tablets, injections or topical preparations; usually short-term for flares.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Thirst, appetite, urination, panting; long-term muscle loss, Cushing\u2019s syndrome and infections.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Serious dose- and duration-related risks with prolonged use; do not stop abruptly.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Long-term risks are well documented.<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Atopica (ciclosporin)<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Oral; effects often develop in 2\u20136 weeks.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Digestive upset, gum overgrowth, skin changes.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Immunosuppression; risks involving infections, tumours, vaccines and interactions.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Extensive experience; used for chronic disease control.<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Antihistamines, e.g. cetirizine<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Oral; sometimes useful for mild or seasonal itching.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Drowsiness, lethargy, gastrointestinal signs; sometimes restlessness.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Often insufficient for severe atopic itching; caution with combination products.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Long experience, but variable effectiveness between dogs.<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Zenrelia (ilunocitinib)<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Once-daily tablet; JAK inhibitor.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Digestive upset, lethargy; US studies also reported blood and liver changes, infections and skin growths.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Monitor for tumours and infections; separate US vaccination warning.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Data beyond six months are limited.<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\" style=\"padding:10px;border:1px solid #d8e3d3;text-align:left;vertical-align:top\">Numelvi (atinvicitinib)<\/th>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Once-daily tablet; more JAK1-selective.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Digestive upset, lethargy, poor appetite; some laboratory changes.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">US label mentions tumours reported with other JAK inhibitors; immune and infection precautions.<\/td>\n<td style=\"padding:10px;border:1px solid #d8e3d3;vertical-align:top\">Data beyond six months are limited.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<p class=\"fendaf-table-note\" style=\"font-size:.92em;color:#555\">Note: a symptom occurring during treatment does not automatically prove that the medicine caused it. For example, a skin infection may also result from a flare-up of the underlying allergy. Percentages from different studies cannot be compared directly.<\/p>\n<h2>Why lumps and tumours deserve special attention<\/h2>\n<p>For me, a warning about tumours is not just another line in a package leaflet. Even a benign growth may require tests, surgery or prolonged monitoring. Malignant disease can affect both a dog&#8217;s lifespan and quality of life. But we must distinguish between an event observed during treatment, an official warning and a demonstrated risk caused by the medicine. They are not the same thing.<\/p>\n<p>The official information for Apoquel, Atopica and Zenrelia includes precautions related to tumours. The US prescribing information for Numelvi notes reports of benign and malignant tumours in dogs treated with other JAK inhibitors. The magnitude of any long-term tumour risk with Numelvi itself is unknown. The European product information for Cytopoint does not contain a comparable tumour warning, but that does not make the injection entirely risk-free.<\/p>\n<p>Dog owners should have the opportunity to learn about these important warnings before starting treatment. The absence of proof of a widespread increase in tumours in studies is not a reason to downplay a serious warning. Equally, the presence of a warning should not be presented as proof that the risk is necessarily large or causally established.<\/p>\n<h2>Apoquel: rapid relief from itching<\/h2>\n<p>Apoquel (oclacitinib) inhibits JAK signalling pathways and often reduces itching and inflammation quickly. The usual schedule starts with twice-daily dosing for up to two weeks, followed by once daily. Some dogs become itchier again when the dosing frequency changes. A <a href=\"https:\/\/fendaf.ee\/en\/health\/apoquel-safety\/\">separate FendaF article<\/a> covers Apoquel in more detail.<\/p>\n<p>Official safety information lists gastrointestinal upset, lethargy, infection-related precautions and restrictions for dogs under 12 months. Pyoderma, yeast-related dermatitis, ear infections or inflammation between the toes may appear during Apoquel treatment. This raises a reasonable question: why does the adverse-reaction information for an anti-itch medicine mention skin problems that themselves cause itching? Some may be associated with the medicine; others may reflect the underlying allergy or a concurrent infection. Distinguishing between them requires examining the dog, not drawing conclusions from timing alone.<\/p>\n<p>We have considerably more data on longer-term use of Apoquel than on Zenrelia or Numelvi, which reached the European market in 2025. Longer experience does not remove the need to monitor blood counts, general health, infections and possible tumours. Some integrative veterinarians are particularly concerned that rapid relief from itching can distract from investigating the underlying cause of skin disease. I do not want that question to disappear, but the claim that Apoquel \u201cpermanently destroys the immune system\u201d is not supported by current evidence.<\/p>\n<h2>Cytopoint: a different mechanism, but not without side effects<\/h2>\n<p>Cytopoint (lokivetmab) is a monoclonal antibody that binds to the itch-signalling protein IL-31. It is injected under the skin, often about every four weeks. Unlike JAK inhibitors, it does not affect inflammatory signalling as broadly. It works well for some dogs; for others, especially when skin lesions are severe, blocking the itch signal alone may not be enough.<\/p>\n<p>The European product information lists rare hypersensitivity reactions, including anaphylaxis, facial swelling and hives, as well as vomiting, diarrhoea and neurological signs such as poor coordination or seizures. Signs of immune-mediated disease have been reported very rarely. These possible reactions should not be hidden behind the blanket statement that \u201cthe injection is safe\u201d.<\/p>\n<p>Cytopoint&#8217;s European product information does not carry the same tumour warning as certain other systemic allergy medicines. If this difference matters to an owner, it is a reasonable point to discuss. However, the veterinarian still needs to assess whether Cytopoint adequately controls the individual dog&#8217;s inflammation and itching, while continuing to investigate possible infections and allergens.<\/p>\n<h2>Corticosteroids: short-term relief and the cost of prolonged use<\/h2>\n<p>Prednisolone and other systemic corticosteroids can reduce inflammation and itching very rapidly during a severe allergic flare. The updated ICADA guidelines for canine atopic dermatitis recommend them primarily for controlling acute flares and caution against the frequent adverse effects of long-term oral use. Prolonged steroid treatment may nevertheless be justified for another illness or in a complicated situation. For allergies, though, it should not quietly become the default solution for years.<\/p>\n<p>Increased thirst, urination, appetite and panting can occur even during short courses. With prolonged use come increased infection risk, thinner skin, slower wound healing, signs of Cushing&#8217;s syndrome, changes in blood glucose and suppression of the body&#8217;s own cortisol production. The last of these is why long-term steroid therapy must not be stopped abruptly without veterinary guidance.<\/p>\n<h3>Muscle loss is not a cosmetic side effect<\/h3>\n<p>One side effect owners often fail to associate with steroids is muscle wasting, or steroid myopathy. Glucocorticoids promote the breakdown of muscle proteins. The result may be visible as loss of muscle over the hindquarters, smaller thigh and gluteal muscles, difficulty standing up or trouble with stairs. An owner might attribute these changes to age or joint disease, when long-term steroid treatment could be one contributing factor.<\/p>\n<p>I have heard clients express surprise when they realise that their dog&#8217;s loss of muscle may be connected to steroid treatment. That is why prolonged treatment should be monitored not just through body weight, but also muscle mass and mobility. I would pay particular attention to this in senior dogs. The earlier a possible problem is noticed, the better the opportunity to adjust the treatment plan. With long-acting steroid injections, it is also important to understand that an injection already given cannot simply be switched off.<\/p>\n<p>Integrative veterinarian Dr Judy Morgan has criticised the routine long-term use of steroids. On this point, the direction of her caution broadly agrees with conventional veterinary guidelines: use the lowest effective dose, for as short a time as possible, with a clear follow-up plan.<\/p>\n<h2>Atopica: slower onset and long-term immune modulation<\/h2>\n<p>Atopica contains ciclosporin (cyclosporine). It inhibits T-cell activation and is used as maintenance treatment for chronic atopic dermatitis, but it does not usually relieve severe itching on the first day. Improvement may develop over two to four weeks and, in some dogs, may take up to six weeks. Once the condition improves, less frequent dosing may be possible.<\/p>\n<p>The most common adverse effects involve the digestive tract, particularly vomiting and diarrhoea. Gum overgrowth, skin changes and other reactions may also occur. Key precautions concern immunosuppression, infection risks, restrictions related to neoplastic disease and interactions with other medicines. The official US label describes Atopica as a systemic immunosuppressant and warns of increased susceptibility to infections and neoplasia.<\/p>\n<p>Atopica has decades of clinical use behind it, an important advantage when assessing long-term safety compared with newer treatments. But that does not eliminate every risk. During long-term therapy, it makes sense to monitor the dog&#8217;s general condition and discuss blood tests according to symptoms and concurrent illnesses. Particular caution is needed when combining several medicines that affect immune function.<\/p>\n<h2>Antihistamines: more suitable for mild than severe atopic itching<\/h2>\n<p>Cetirizine, hydroxyzine and other antihistamines may help some dogs with milder or seasonal allergic itching. Their effects are often too modest and inconsistent, however, for treating established, severe atopic skin inflammation. It would therefore be misleading to present them as direct substitutes for Apoquel or Cytopoint in dogs with serious disease.<\/p>\n<p>Possible side effects include drowsiness, restlessness and gastrointestinal symptoms, and these vary by active ingredient. Combination allergy medicines intended for humans may contain ingredients unsuitable for dogs, so the product and dose should be discussed with a veterinarian first. Beginning with a less intensive option may make sense for mild symptoms, but a dog with persistent severe itching should not be left undertreated.<\/p>\n<h2>Zenrelia: what do studies show, and what did Judy Morgan highlight?<\/h2>\n<p>Zenrelia (ilunocitinib) is a once-daily JAK inhibitor. It was approved in the United States in 2024 and in the European Union in 2025. The medicine can effectively reduce itching and inflammation, but it affects more than one immune signalling pathway. When Zenrelia was first launched, integrative veterinarian Dr Judy Morgan drew attention to study duration, infections, blood count changes and reports involving tumours.<\/p>\n<p>This section draws on Judy Morgan&#8217;s video of 5 January 2025, \u201cZenrelia \u2013 Used for Allergies: Potential Risks &amp; Side Effects\u201d, and a 12-page set of notes made from it. Because those notes summarise the video, I distinguish her emphasis below from updated official US product information and study results. The notes are not an independent clinical trial.<\/p>\n<h3>What did the US 112-day study actually show?<\/h3>\n<p>In a study of dogs with atopic dermatitis, 181 dogs receiving Zenrelia and 87 receiving placebo were followed for up to 112 days. Vomiting or nausea, for example, was observed in 22.1% of the Zenrelia group versus 16.1% of the placebo group; diarrhoea in 19.9% versus 10.3%; and lethargy in 12.2% versus 10.3%. These are proportions of events recorded during treatment, not automatic proof of causation.<\/p>\n<p>A low white blood cell count (leukopenia) was reported in 4.9% of Zenrelia-treated dogs and 1.1% of placebo-treated dogs. Skin growths such as cysts or papillomas were reported in 8.8% versus 4.6%, and lipomas in 3.9% versus 1.1%. One metastatic haemangiosarcoma and one mast cell tumour were recorded in the treatment group. For example, 4.9% means roughly five out of every hundred dogs in this particular treatment group, not a prediction that five out of every hundred dogs will develop the same problem with long-term use. The study was too short to support such a conclusion.<\/p>\n<p>Judy Morgan&#8217;s notes also describe dogs withdrawn from the study because of persistent vomiting, decreased blood cell counts, infections or enlarging skin growths, among other reasons. Official information confirms that treatment was discontinued in some cases following adverse events, but it has not been demonstrated that the medicine caused every tumour or infection described. The findings must also be considered alongside the control group and any pre-existing conditions.<\/p>\n<p>What does a 50% reduction in itching mean in a study? In her 2025 video, Judy Morgan points out that even halving the itch may not be enough for a severely affected dog to justify treatment risks. This is a practical quality-of-life question. However, a study&#8217;s predefined threshold of at least 50% improvement does not mean the medicine can reduce itching by no more than 50%. It is one measure of treatment success; clinical remission, the dog&#8217;s comfort and side effects must also be considered.<\/p>\n<h3>What did the head-to-head study against Apoquel find?<\/h3>\n<p>A randomised, blinded comparison published in 2025 initially enrolled 338 dogs with atopic dermatitis, divided equally between Zenrelia (ilunocitinib) and Apoquel (oclacitinib). Itching decreased similarly in both groups over the first 14 days. After Apoquel&#8217;s usual switch from twice-daily to once-daily dosing, average itch control was better in the Zenrelia group. At day 28, mean itch reduction from baseline was 68.2% with Zenrelia and 59.4% with Apoquel.<\/p>\n<p>By day 112, approximately 77% of dogs in the Zenrelia group and 53% of those in the Apoquel group had reached a near-normal itch score. An important limitation is that the 112-day extension was voluntary: only 154 of the original 338 dogs took part (75 on Zenrelia and 79 on Apoquel). The day-112 results therefore do not mean that all original participants were followed for four months. The study suggests a possible efficacy advantage, not greater long-term safety. The authors were employees of the manufacturer, Elanco, which should be transparent when interpreting the results.<\/p>\n<h3>What can we learn from clinical experience with 100 dogs?<\/h3>\n<p>Veterinary dermatologist Dr Britney Lancelotti describes using Zenrelia in around 100 dogs at her clinic. In her experience, the medicine has generally been well tolerated and helped several dogs whose allergy symptoms were not adequately controlled by previous treatments.<\/p>\n<p>However, experience with around 100 dogs is not enough to draw reliable conclusions about rare adverse reactions or the medicine&#8217;s long-term safety.<\/p>\n<p>For example, if a serious adverse reaction occurs in one dog out of 10,000 on average, a group of 100 dogs has about a 99% probability of not showing a single case. A small clinical experience can therefore give a very reassuring safety picture even when rare but serious risks really exist. This is an illustrative statistical calculation, not the known incidence of any specific Zenrelia adverse reaction. It assumes independent events with equal risk and that reactions are detected.<\/p>\n<p>Lancelotti has also observed reductions in white blood cell counts in some of her patients, although she says the results improved after adjusting the dose. This underscores the practical value of blood monitoring, but it is an observation from a single clinic rather than a controlled study.<\/p>\n<p>Her experience is therefore valuable clinical evidence of what she has observed, but not proof that long-term Zenrelia treatment is risk-free.<\/p>\n<h3>Blood cells, liver values and infections<\/h3>\n<p>The US prescribing information warns of possible persistent or progressive decreases in haemoglobin, haematocrit or red blood cell counts and describes changes in several white blood cell subtypes and platelets. Studies have also noted changes in liver enzymes and other blood chemistry values. These observations should not be simplified into the claim that the medicine \u201cswitches off the bone marrow\u201d: blood abnormalities have been documented, but their mechanisms and significance require assessment in the individual dog.<\/p>\n<p>Zenrelia may increase susceptibility to certain infections. The US label mentions demodicosis, interdigital furunculosis, coccidiosis and pneumonia, among others, and warns of worsening underlying infections. The medicine is not intended for dogs with serious infections; risks need especially careful assessment where there is a history of recurrent infections or tumours. Safety has also not been adequately evaluated when used together with glucocorticoids, ciclosporin or other systemic immunosuppressants.<\/p>\n<p>Judy Morgan recommends checking blood counts and liver values approximately one month after treatment begins. This is her practical monitoring recommendation, not a mandatory schedule for every dog. Nevertheless, the principle of regular monitoring of blood counts and biochemical values is also supported by the 2026 ICADA guidelines, particularly during long-term treatment and where other risk factors exist.<\/p>\n<h3>Vaccination: the concerns raised in 2025 and what changed later<\/h3>\n<p>In her January 2025 video, Judy Morgan discussed severe illnesses observed in a vaccine-response study and the risk of death described in the US warning at that time. The original data described hepatitis and pancreatitis in a dog that died. At the time, illness caused by a vaccine virus in the setting of immunosuppression was considered a possible explanation.<\/p>\n<p>On 19 September 2025, the FDA revised that conclusion. Additional genetic testing of the virus provided evidence for a different adenovirus rather than the vaccine strain used. The US warning about fatal vaccine-induced disease was therefore removed. The warning that dogs taking Zenrelia may develop an inadequate immune response to vaccination remained. US product information requires stopping treatment between 28 days and three months before vaccination and withholding it for at least 28 days afterwards. The European product information does not impose the same mandatory interruption. Owners and veterinarians should follow the product information applicable in their country.<\/p>\n<p>Two facts matter at the same time: Judy Morgan drew attention to a serious study finding that warranted scrutiny, and later evidence changed one specific causal interpretation. Neither fact should be erased. This is also a useful example of why both regulatory documents and integrative clinical observations need to be revisited as knowledge evolves.<\/p>\n<p>In her September 2025 video, veterinary dermatologist Dr Britney Lancelotti also discusses a later booster-vaccination study in which, according to her, dogs receiving Zenrelia mounted a vaccine response. However, booster responses cannot automatically be extrapolated to the primary vaccination of previously unvaccinated young dogs. In her spoken explanation, Lancelotti also reverses the US pre- and post-vaccination interruption periods. The precise intervals stated above come from the FDA&#8217;s updated prescribing information, not from the video. US and European warnings should not be conflated.<\/p>\n<h3>Is Zenrelia suitable for long-term use?<\/h3>\n<p>The 2026 ICADA guidelines consider Zenrelia an effective option both for flares and for maintenance treatment, but note the lack of long-term safety data beyond six months. This does not mean the medicine automatically becomes dangerous after six months. It means a six-month study cannot assess every rare or delayed effect that might emerge after a year or several years. Post-marketing safety surveillance of new medicines is therefore important.<\/p>\n<p>In January 2025, the FDA also warned the manufacturer, Elanco, about misleading safety presentations or insufficient disclosure of important risks in Zenrelia advertising. This does not itself prove that the medicine is ineffective or dangerous, but it highlights why full product information must reach dog owners.<\/p>\n<h2>Numelvi: is a more selective JAK inhibitor safer?<\/h2>\n<p>Numelvi (atinvicitinib) is a newer medicine with greater selectivity for JAK1. It received marketing authorisation in the European Union in 2025 and in the United States in 2026. Given orally once a day, it may reduce itching quickly in some dogs. Selectivity matters to the mechanism of action, but it does not yet establish better long-term safety.<\/p>\n<p>European product information lists vomiting, diarrhoea, lethargy and reduced appetite as common adverse effects. The US prescribing information additionally highlights infection risks and reports of benign and malignant tumours in dogs treated with other JAK inhibitors. This is a class-related warning, not proof that Numelvi itself causes tumours. Numelvi&#8217;s clinical field safety study lasted up to 28 days, while a six-month safety study also used doses above the recommended level. Data beyond six months remain limited. I would not automatically leave Numelvi as a \u201clast resort\u201d simply because it is new. If I were considering it at all, it could be reasonable to discuss it among the initial options. That does not prove that using Numelvi first would reduce tumour risk. Nor does previous treatment with Apoquel or Cytopoint automatically rule out prescribing Numelvi. What matters is that the treatment sequence should not be predetermined blindly, and that the owner understands both documented risks and gaps in knowledge.<\/p>\n<h2>Integrative veterinarians&#8217; criticism and the limits of what we know<\/h2>\n<p>Beyond efficacy, Dr Judy Morgan&#8217;s criticism of Zenrelia centres on the duration of safety studies, possible consequences of immune modulation and what official adverse-event tables mean for an owner&#8217;s real-life experience. She has expressed a general precautionary preference not to rush into using brand-new medicines before several years, often around five years, of experience have accumulated. This is a clinical preference, not an official threshold after which a medicine automatically becomes safe.<\/p>\n<p>Lancelotti also describes an 11-year-old West Highland White Terrier named Rosie, whose itch score fell from nine out of ten to two after starting Zenrelia and receiving treatment for concurrent infections. The case shows how valuable symptom relief can be for an individual dog. But the improvement cannot be attributed to Zenrelia alone, because the accompanying infections were also treated. The difference between Judy Morgan and Lancelotti lies mainly in which risks they consider acceptable, not in one of them claiming that serious adverse effects are impossible.<\/p>\n<p>Some integrative veterinarians have clinical observations that research has not yet resolved conclusively. These should not automatically be dismissed. A recurring observation can be an important safety signal and a reason for further investigation. But we must be equally clear when other explanations cannot be ruled out or causation cannot be established. One does not cancel out the other: research is one source of knowledge, and carefully documented clinical experience another, though they carry different evidential weight.<\/p>\n<p>The same principle applies to conventional veterinary medicine. Conclusions drawn from research may be refined as new evidence emerges. The change to Zenrelia&#8217;s vaccination warning illustrates this very clearly. I can therefore understand why some veterinarians prefer to wait before prescribing new medicines, while owners also need to know that severe untreated atopic dermatitis can considerably harm a dog.<\/p>\n<h2>What else can we do beyond suppressing symptoms?<\/h2>\n<p>With allergies, it is worth looking for possible triggers: fleas and other parasites, food allergies, environmental allergens, bacterial or yeast infections, and a compromised skin barrier. Not every itchy dog itches for the same reason. While symptoms are being managed, targeted diagnostics and changes to the dog&#8217;s environment can help identify causes that are not yet known.<\/p>\n<p>Among FendaF customers there have been dogs whose wellbeing and skin condition improved after switching to a Winner Plus food better suited to them. These experiences matter, but they do not mean every dog with atopic dermatitis can be \u201ccured\u201d without medication, or that the effect of any particular food has been proven in a study. When a food allergy is suspected, a properly conducted elimination diet matters more than random food changes. Moisturising and topical skin care, treatment of infections and an allergy-aware environment can reduce the burden of symptoms and sometimes the need for medication. For atopic dermatitis driven by environmental allergens, the 2026 ICADA guidelines recommend considering allergen-specific immunotherapy. It differs from rapid itch relief: the aim is to influence the course of the allergic response over time. Supportive measures may be enough in milder cases; in severe disease they complement effective treatment rather than automatically replace it.<\/p>\n<h2>Choosing a medicine and the owner&#8217;s informed consent<\/h2>\n<p>If I had to choose between allergy medicines for my own dog, I would begin by examining their possible adverse effects. I would prefer to start with a medicine that carries as low a risk of serious adverse reactions as possible given my dog&#8217;s health. I would particularly want to know whether any harm could be reversed, how long the medicine has been in use and what is known about its long-term safety. Because if my dog happens to be the one who experiences a rare but serious reaction, knowing that it is statistically uncommon does not undo the consequences.<\/p>\n<p>However, risk cannot be judged simply by counting entries in a side-effect list. An older medicine may have a longer list precisely because it has been monitored for longer. For an owner, one rare but serious and irreversible reaction may matter more than several common but temporary effects. We discuss the long-term use of medicines in a <a href=\"https:\/\/fendaf.ee\/tervis\/ravimid-ja-nende-pikaaegne-kasutamine\/\" lang=\"et\">separate FendaF article (in Estonian)<\/a>.<\/p>\n<p>When official prescribing information identifies a potentially serious risk, owners should hear about it before treatment begins. The veterinarian&#8217;s role is to explain the expected benefits, common side effects, rare but serious outcomes and reasonable alternatives, and to make full product information available. The owner decides whether to give informed consent to treatment based on the circumstances of their own dog. That does not mean the owner prescribes the medicine; the veterinarian remains responsible for the medical indication and an appropriate regimen. But the final decision on the choice and use of the medicine rests with the owner.<\/p>\n<p>Sometimes a medicine is essential and there are very few alternatives. Even then, the duty to inform does not disappear. Particularly when several medicines are used together or treatment continues for years, owners need to know what to monitor, what could indicate an interaction and when to seek help urgently. Informed consent is not merely saying \u201cyes\u201d to a pill or an injection.<\/p>\n<h2>What should you monitor during treatment?<\/h2>\n<ul class=\"fendaf-monitoring-list\">\n<li>At the start: record symptoms, the condition of the skin and ears, body weight, all medicines being used and any baseline tests recommended by the veterinarian.<\/li>\n<li>During treatment: alongside itching, monitor appetite, stools, energy, thirst, possible infections and any new skin growths.<\/li>\n<li>Over the longer term: ask whether blood counts, liver and kidney values or other tests are needed and how often; guidelines stress regular monitoring with JAK inhibitors.<\/li>\n<li>If a severe reaction develops: seek emergency veterinary care immediately for facial swelling, breathing difficulty, seizures, collapse or a seriously deteriorating general condition. For other suspected side effects, contact your veterinarian and document what has changed.<\/li>\n<li>Do not stop steroids abruptly on your own. Changes to other medicines also need an appropriate plan, particularly around vaccination or a serious infection.<\/li>\n<\/ul>\n<h2>In conclusion<\/h2>\n<p>Treating a dog&#8217;s allergies need not be a choice between blindly trusting medicines and avoiding them altogether. Sometimes medication gives a dog back restful sleep, comfort and the freedom to move. At the same time, owners have a right to know which adverse effects have been observed, which risks are established, which questions remain unanswered, and what could be done to reduce the need for medication where possible.<\/p>\n<p>For me, good treatment means considering the individual dog and its quality of life. \u201cGenerally well tolerated\u201d does not automatically mean \u201csafe for my dog\u201d. That is why possible serious risks must be discussed before treatment starts, not only after something goes wrong.<\/p>\n<h2>Sources<\/h2>\n<ol class=\"fendaf-sources\">\n<li>Mueller RS, Banovic F, Bensignor E, Santoro D, Nuttall T (2026). Treatment of Canine Atopic Dermatitis: Updated Guidelines From the International Committee on Allergic Diseases of Animals (ICADA). Veterinary Dermatology. DOI: 10.1111\/vde.70128. <a href=\"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.70128\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>FDA \/ DailyMed (2026). Zenrelia (ilunocitinib tablets), official US prescribing information, updated 29 April 2026. <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?audience=consumer&#038;setid=adf9a1c8-31bd-4301-ac25-814d13f34cae\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>FDA (19 September 2025). Animal Drug Safety-Related Labeling Changes: Zenrelia. <a href=\"https:\/\/www.fda.gov\/animal-veterinary\/drug-labels\/animal-drug-safety-related-labeling-changes\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>FDA (19 September 2025). Zenrelia Supplemental Freedom of Information Summary, NADA 141-585. <a href=\"https:\/\/animaldrugsatfda.fda.gov\/adafda\/app\/search\/public\/document\/downloadFoi\/17467\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>FDA (28 January 2025). Warning Letter to Elanco Animal Health concerning Zenrelia promotional materials. <a href=\"https:\/\/www.fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/elanco-animal-health-695170-01282025\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>European Medicines Agency (2025). Zenrelia: European Public Assessment Report and product information. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/zenrelia\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>European Medicines Agency (2025). Numelvi: European Public Assessment Report and product information. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/numelvi\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>FDA \/ DailyMed (2026). Numelvi (atinvicitinib tablets): official US prescribing information. <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=4926fcfa-20a0-46d8-aca2-53ae88332a31&#038;type=display\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>European Medicines Agency (2017\u20132025). Cytopoint (lokivetmab): European Public Assessment Report and product information. <a href=\"https:\/\/www.ema.europa.eu\/en\/medicines\/veterinary\/EPAR\/cytopoint\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>European Medicines Agency \/ EU (2025). Cytopoint: Summary of Product Characteristics. <a href=\"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230804160062\/anx_160062_en.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>U.S. National Library of Medicine \/ DailyMed (2026). ATOPICA (cyclosporine capsules): official prescription labeling. <a href=\"https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=99642708-0a9f-4ff0-bc08-f2b18691927e\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>Dr Judy Morgan (5 January 2025). Zenrelia Used for Allergies: Potential Risks &amp; Side Effects. Video and 12-page notes compiled from it. <a href=\"https:\/\/www.youtube.com\/watch?v=JnxvHzOHIEQ\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>Forster S, Boegel A, Despa S, Trout C, King S (2025). Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Veterinary Dermatology, 36(2):165\u2013176. DOI: 10.1111\/vde.13319. PMID: 39757965. <a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC11885073\/\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<li>Lancelotti B (1 September 2025). Is Zenrelia Safe for Your Pet? Breaking Down the Risks and Benefits. Your Vet Wants You to Know, video and published transcript. <a href=\"https:\/\/www.youtube.com\/watch?v=X_giG0HmtBc\" target=\"_blank\" rel=\"noopener noreferrer\">Source<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Allergy medications for dogs can quickly relieve severe itching and noticeably improve a dog&#8217;s quality of life. But when treatment may continue long term, as an owner I want to know more than that a medicine is \u201cgenerally well tolerated\u201d. What side effects are possible? How long have they been studied? What risks should I [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":179947,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[698],"tags":[],"class_list":["post-193175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"acf":[],"featured_image_src":{"landsacpe":["https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp",300,300,false],"list":["https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp",300,300,false],"medium":["https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_-300x300.webp",300,300,true],"full":["https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp",300,300,false]},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dog allergy medications: effects, side effects and risks | FendaF<\/title>\n<meta name=\"description\" content=\"Compare Apoquel, Cytopoint, Atopica, Zenrelia and Numelvi: how they work, side effects, tumour warnings and risks of long-term treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dog allergy medications: effects, side effects and risks | FendaF\" \/>\n<meta property=\"og:description\" content=\"Compare Apoquel, Cytopoint, Atopica, Zenrelia and Numelvi: how they work, side effects, tumour warnings and risks of long-term treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/\" \/>\n<meta property=\"og:site_name\" content=\"FendaF - thinking of your pet!\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/fendafmaius\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-10T08:52:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-17T16:14:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"300\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Piret Oper\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@piret.oper\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Piret Oper\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/\"},\"author\":{\"name\":\"Piret Oper\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/person\\\/bac9e619d6199be4b1614eba36ac7c34\"},\"headline\":\"How safe are allergy medications for dogs? How different treatments work, their risks and alternatives\",\"datePublished\":\"2023-03-10T08:52:40+00:00\",\"dateModified\":\"2026-11-17T16:14:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/\"},\"wordCount\":4820,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp\",\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/\",\"name\":\"Dog allergy medications: effects, side effects and risks | FendaF\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp\",\"datePublished\":\"2023-03-10T08:52:40+00:00\",\"dateModified\":\"2026-11-17T16:14:59+00:00\",\"description\":\"Compare Apoquel, Cytopoint, Atopica, Zenrelia and Numelvi: how they work, side effects, tumour warnings and risks of long-term treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp\",\"contentUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp\",\"width\":300,\"height\":300,\"caption\":\"allergiaravim\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/health\\\/kui-ohutud-on-allergiaravimid\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/home4\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How safe are allergy medications for dogs? How different treatments work, their risks and alternatives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/\",\"name\":\"FendaF - thinking of your pet!\",\"description\":\"Treats and quality dry food for your pet\",\"publisher\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#organization\",\"name\":\"FendaF O\u00dc\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Fendaf_logo_taustata.png\",\"contentUrl\":\"https:\\\/\\\/fendaf.ee\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Fendaf_logo_taustata.png\",\"width\":7262,\"height\":4799,\"caption\":\"FendaF O\u00dc\"},\"image\":{\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/fendafmaius\\\/\",\"https:\\\/\\\/www.instagram.com\\\/fendaf.ee\\\/\",\"https:\\\/\\\/www.pinterest.com\\\/3a00893ff1d6c42bef9ee783f17b79\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fendaf.ee\\\/en\\\/#\\\/schema\\\/person\\\/bac9e619d6199be4b1614eba36ac7c34\",\"name\":\"Piret Oper\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g\",\"caption\":\"Piret Oper\"},\"sameAs\":[\"https:\\\/\\\/www.instagram.com\\\/explore\\\/tags\\\/fendafmaius\\\/\",\"https:\\\/\\\/x.com\\\/piret.oper\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dog allergy medications: effects, side effects and risks | FendaF","description":"Compare Apoquel, Cytopoint, Atopica, Zenrelia and Numelvi: how they work, side effects, tumour warnings and risks of long-term treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/","og_locale":"en_US","og_type":"article","og_title":"Dog allergy medications: effects, side effects and risks | FendaF","og_description":"Compare Apoquel, Cytopoint, Atopica, Zenrelia and Numelvi: how they work, side effects, tumour warnings and risks of long-term treatment.","og_url":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/","og_site_name":"FendaF - thinking of your pet!","article_publisher":"https:\/\/www.facebook.com\/fendafmaius\/","article_published_time":"2023-03-10T08:52:40+00:00","article_modified_time":"2026-11-17T16:14:59+00:00","og_image":[{"width":300,"height":300,"url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp","type":"image\/webp"}],"author":"Piret Oper","twitter_card":"summary_large_image","twitter_creator":"@piret.oper","twitter_misc":{"Written by":"Piret Oper","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#article","isPartOf":{"@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/"},"author":{"name":"Piret Oper","@id":"https:\/\/fendaf.ee\/en\/#\/schema\/person\/bac9e619d6199be4b1614eba36ac7c34"},"headline":"How safe are allergy medications for dogs? How different treatments work, their risks and alternatives","datePublished":"2023-03-10T08:52:40+00:00","dateModified":"2026-11-17T16:14:59+00:00","mainEntityOfPage":{"@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/"},"wordCount":4820,"commentCount":0,"publisher":{"@id":"https:\/\/fendaf.ee\/en\/#organization"},"image":{"@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#primaryimage"},"thumbnailUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp","articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/","url":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/","name":"Dog allergy medications: effects, side effects and risks | FendaF","isPartOf":{"@id":"https:\/\/fendaf.ee\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#primaryimage"},"image":{"@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#primaryimage"},"thumbnailUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp","datePublished":"2023-03-10T08:52:40+00:00","dateModified":"2026-11-17T16:14:59+00:00","description":"Compare Apoquel, Cytopoint, Atopica, Zenrelia and Numelvi: how they work, side effects, tumour warnings and risks of long-term treatment.","breadcrumb":{"@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#primaryimage","url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp","contentUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp","width":300,"height":300,"caption":"allergiaravim"},{"@type":"BreadcrumbList","@id":"https:\/\/fendaf.ee\/en\/health\/kui-ohutud-on-allergiaravimid\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fendaf.ee\/en\/home4\/"},{"@type":"ListItem","position":2,"name":"How safe are allergy medications for dogs? How different treatments work, their risks and alternatives"}]},{"@type":"WebSite","@id":"https:\/\/fendaf.ee\/en\/#website","url":"https:\/\/fendaf.ee\/en\/","name":"FendaF - thinking of your pet!","description":"Treats and quality dry food for your pet","publisher":{"@id":"https:\/\/fendaf.ee\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fendaf.ee\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fendaf.ee\/en\/#organization","name":"FendaF O\u00dc","url":"https:\/\/fendaf.ee\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fendaf.ee\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2020\/03\/Fendaf_logo_taustata.png","contentUrl":"https:\/\/fendaf.ee\/wp-content\/uploads\/2020\/03\/Fendaf_logo_taustata.png","width":7262,"height":4799,"caption":"FendaF O\u00dc"},"image":{"@id":"https:\/\/fendaf.ee\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/fendafmaius\/","https:\/\/www.instagram.com\/fendaf.ee\/","https:\/\/www.pinterest.com\/3a00893ff1d6c42bef9ee783f17b79\/"]},{"@type":"Person","@id":"https:\/\/fendaf.ee\/en\/#\/schema\/person\/bac9e619d6199be4b1614eba36ac7c34","name":"Piret Oper","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ce6313a9befc50de074345e0ca53cf60cf828d119f4018320c351500a06e7f3?s=96&d=mm&r=g","caption":"Piret Oper"},"sameAs":["https:\/\/www.instagram.com\/explore\/tags\/fendafmaius\/","https:\/\/x.com\/piret.oper"]}]}},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/fendaf.ee\/wp-content\/uploads\/2023\/03\/Kui-ohutud-on-allergiaravimid-_600-\u00d7-600-px_.webp","_links":{"self":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts\/193175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/comments?post=193175"}],"version-history":[{"count":2,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts\/193175\/revisions"}],"predecessor-version":[{"id":193180,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/posts\/193175\/revisions\/193180"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/media\/179947"}],"wp:attachment":[{"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/media?parent=193175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/categories?post=193175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fendaf.ee\/en\/wp-json\/wp\/v2\/tags?post=193175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}